Cardiovascular system – Page 2

Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults

9 months ago talkbio0Tagged Approved, Cardiovascular system, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity, Risk, semaglutide, UK, Wegovy

Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

9 months ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures

Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease

11 months ago11 months ago talkbio0Tagged Cardiovascular system, Cessation of life, Chronic Kidney Diseases, Diabetes, Failure (biologic function), Kidney, Mortality Vital Statistics, Nordisk, Obesity, semaglutide, Wegovy

** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment